The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database
|
|
- Bertina Cooper
- 6 years ago
- Views:
Transcription
1 DOI: /j x Gynaecological oncology The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database R Rouzier, a,b C Bergzoll, a J-L Brun, c G Dubernard, a F Selle, d S Uzan, a,b C Pomel, e, * E Daraï a,b,* a Department of Gynaecology, Hopital Tenon, Paris, France b INSERM-UMR_S 938, University Pierre et Marie Curie, Paris, France c Department of Obstetrics and Gynaecology, University Hospital Pellegrin, Bordeaux, France d Department of Medical Oncology, Hopital Tenon, INSERM-UMR_S 938, Paris, France e Department of Surgery, Centre Jean-Perrin (Centre de Lutte Contre le Cancer d Auvergne), Clermont-Ferrand, France Correspondence: R Rouzier, Department of Gynaecology, 4 Rue de la Chine, Paris, France. roman.rouzier@tnn.aphp.fr Accepted 3 May Published Online 18 June Objective The therapeutic role of lymphadenectomy on the survival in patients with ovarian cancer is controversial. The aim of this study was to evaluate the survival impact of lymphadenectomy, depending on the disease stage and extent of the surgery. Design The surveillance, epidemiology, and end results (SEER) registry provided ovarian cancer data from 17 registries. Setting Surveillance, Epidemiology, and End Results database. Population The study population comprised patients. Methods Survival was studied according to the number of lymph nodes removed, with stratifications on disease stage and extent of surgery. Main outcome measure The 5-year cause-specific survival rate. Results The median follow up for patients alive at the last followup visit was 39 months. The five-year cause-specific survival rates were 37, 62, and 71% for the groups in which no lymph nodes were examined, in which between one and nine nodes were examined, and in which ten or more nodes were examined, respectively (P < 0.001). Avoiding lymphadenectomy was deleterious in all stages of the disease. It was maximal for International Federation of Gynecology and Obstetrics (FIGO) stage-ii patients, but there was no significant interaction between stage and extent of lymphadenectomy. The cause-specific survival was found to significantly increase when more nodes were resected, even if the surgical procedure consisted of debulking surgery or a pelvic exenteration. Conclusion Our study suggests a beneficial effect of lymphadenectomy in epithelial ovarian tumours, regardless of the stage of disease and extent of surgery. However, potential biases inherent to this retrospective methodology, such as staging migration, defining the extent of residual disease, and the possibility that thorough lymphadenectomy may reflect the quality of cytoreductive surgery, preclude any formal conclusions on the therapeutic role of lymphadenectomy. Keywords Cancer, lymphadenectomy, ovary, staging, therapeutic role. Please cite this paper as: Rouzier R, Bergzoll C, Brun J, Dubernard G, Selle F, Uzan S, Pomel C, Daraï E. The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG 2010;117: Ovarian cancer is one the highest causes of cancer deaths in women in Western countries. 1 Treatment of most ovarian cancers consists of surgery and chemotherapy. Primary cytoreductive surgery is the cornerstone treatment of ovarian cancer, and is a major prognostic factor. 2 Ovarian cancer principally disseminates by two routes: transcoelomic spread and through lymphatics. Since 1986, FIGO classification takes into account these two routes: stage-iiic disease includes patients with peritoneal implants larger than * Co-senior authors. 2 cm outside the pelvis, and/or metastatic retroperitoneal lymph nodes. 3 If maximal cytoreduction of peritoneal disease is widely accepted as a major determinant of survival, the therapeutic value of systematic lymphadenectomy in women with ovarian cancer remains controversial, even if it has been shown to be feasible and safe. Retrospective studies have suggested a significant survival advantage following systematic lymphadenectomy; 4,5 however, a prospective randomised clinical trial demonstrated a progression-free survival benefit, but no overall survival benefit, when systematic lymphadenectomy was compared with a ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1451
2 Rouzier et al. selected lymphadenectomy limited to palpable bulky nodes. 6 Additional data are thus needed to explore the value of lymphadenectomy in patients with all-stage ovarian cancer. Recently, Chan et al. have performed two large population-based studies to investigate the role of lymphadenectomy in patients with advanced-stage ovarian cancers. Their studies analysed the disease-specific survival outcomes of 6686 patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage-i ovarian cancer, and patients diagnosed with advanced-stage epithelial ovarian cancer, to demonstrate the potential role of lymph node dissection. 7,8 Because the two analyses were separated in two different publications, the staging effect of lymphadenectomy can be hardly distinguished from the therapeutic effect. Moreover, residual disease is an important prognostic factor, 2 and the effect of lymphadenectomy should be studied with respect to this variable or a marker of maximal surgical effort. Therefore, we conducted a population-based study to analyse the therapeutic effect of lymphadenectomy on survival after adjusting for disease stage and extent of surgery. Methods Using the surveillance, epidemiology, and end results (SEER) registry ( public use data tapes provided from 17 registries (Alaska Natives, Atlanta, Connecticut, Detroit, Hawaii, Iowa, Los Angeles, New Mexico, San Francisco Oakland, San Jose Monterey, Seattle Puget Sound, Rural Georgia, Utah, Greater California, Kentucky, Louisiana, and New Jersey), we identified patients diagnosed with ovarian carcinoma from 1 January 1988 to 31 December The SEER registry includes patients from 1973, but information concerning the disease extent (nodes) and type of surgery is unavailable for patients managed before Case listings were generated using codes specific for primary organ site, extent of disease, age at diagnosis, year of diagnosis, survival in months, and cause of death. Lymphadenectomy extent was characterised by the number of lymph nodes removed, and lymph node status was characterised by the number of metastatic nodes reported. Analysis was restricted to patients with information available concerning the number of lymph nodes removed (code < 95). Patients were grouped based on the extent of surgery: hysterectomy versus no hysterectomy, omentectomy versus no omentectomy, and debulking or exenteration versus no debulking or exenteration. Four groups were generated for the multivariate analysis (no hysterectomy, hysterectomy, omentectomy, and debulking or exenteration). In the SEER database, debulking or exenteration were defined as the partial or total removal of the tumour mass, and could involve removal at multiple organ sites. We considered that debulking surgery or exenteration correspond to an extensive ovarian and peritoneal cytoreduction. To study the effect of the extent of lymphadenectomy, we used the same cut-offs as Chang et al. 7,8, and divided the cohort into three groups: no lymph nodes removed; between one and nine (limited lymphadenectomy) lymph nodes removed; and ten or more lymph nodes removed (extensive lymphadenectomy). Overall survival (OS), cause-specific survival (CSS), and other cause survival (OCS) were measured by SEER as the time from diagnosis to date of death, and date of last follow up, respectively. We used the Kaplan Meier product limit method to describe OS, CSS, and OCS, and the logrank test to assess differences between patient groups. Survival was studied according to the number of lymph nodes resected, with stratification on disease stage and the extent of surgery. The multivariate survival analysis was performed using a Cox proportional hazard model. The multivariate model included age (<50 versus >50 years), FIGO stage, histological grade and cell type, extent of surgery, number of resected lymph nodes, and lymph node status. All tests were two tailed, and P < 0.05 was considered to denote a significant difference. All analyses were performed using the R package with the Design, Hmisc, and Survival libraries ( Results We identified patients with ovarian cancer during the study period. Information on the number of lymph nodes harvested was unavailable for 5055 patients. Therefore, the study population comprised patients. The mean number of lymph nodes removed was 3.7 (standard deviation, 8.2). No lymph nodes were harvested in patients (62%). The median patient age was 64 years (mean, 63 years; standard deviation, 16 years). Table 1 summarises the patient characteristics according to the number of nodes removed: most patients were white. Patients less than 50 years of age were significantly more likely to have a lymphadenectomy: 25 and 23% had between one and nine nodes, and ten or more nodes, resected, respectively. In patients older than 50 years, 16 and 12% had between one and nine nodes, and ten or more nodes, resected, respectively. Other differences between the populations of women who underwent lymphadenectomy and those who did not are reported in Table 1. The median follow up was 39 months (range, months). In the whole population, the 5- and 10-year overall survival rates were 38 and 28%, respectively. CSS rates were 46 and 38% at 5 and 10 years, respectively. The 5-year CSS rates were 37, 62, and 71% for the groups in which no 1452 ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
3 Lymph node resection in ovarian cancer Table 1. Patient characteristics according to the number of nodes resected No lymphadenectomy Lymphadenectomy 1 9 nodes Lymphadenectomy >10 nodes n % n % n % Age <50 years < >50 years Race Black < Asian White Hispanic NA Other Site of treatment Central < East West FIGO stage I < II III IV NA Histologic type clear cell < sex cord stromal epithelial germ cell sarcoma Histologic grade < Unknown lymph nodes were examined, in which between one and nine nodes were examined, and in which ten or more nodes were examined, respectively (P < 0.001). When restricted to epithelial tumours (including clear cell; n = ; Figure 1), the 5-year CSS rates were 34, 61, and 70% for the groups in which no lymph nodes were examined, in which between one and nine nodes were examine, and in which ten or more nodes were examined, respectively (P < 0.001). We also studied OCS to evaluate whether the lymphadenectomised and non-lymphadenectomised women were at similar risk of death from other causes than ovarian cancer. Among the deaths, 23, 20, and 18% were caused by disease other than ovarian cancer for the groups in which P no lymph nodes were examined, in which between one and nine nodes were examined, and in which ten or more nodes were examined, respectively (P < 0.001). This demonstrates the patient selection for lymphadenectomy in the SEER database. Nonetheless, the difference of survival between groups observed for OCS (13%) was statistically different from the difference for CSS (36%) (P < 0.001). Therefore, even if groups with and without lymphadenectomy are different, the value of lymphadenectomy can be considered as independent of patient health status. As lymphadenectomy is aimed to upstage I IIIB disease to IIIC disease, the extent of lymphadenectomy in these patients may reflect the quality of staging. When FIGO stages were studied separately, the beneficial effect of lymphadenectomy was observed for all FIGO stages (Figure 2). The deleterious effect of the omission of lymphadenectomy was more pronounced in patients with FIGO stage II compared with stage I (Figure 2). The survival difference between the groups in which between one and nine nodes were examined and in which ten or more nodes were examined was higher in patients with FIGO stage-iiia and -IIIB disease. These results suggest that the detrimental effect related to the omission of lymphadenectomy was higher in patients with a higher risk of nodal involvement, namely patients with a higher disease stage. We also studied CSS with a classification based on the extent of surgery. This is of particular interest in patients with locally advanced disease stages, where the cytoreduction and the extent of surgery may influence the outcome. The 5- and 10-year CSS rates were found to increase when more nodes were resected, regardless of the extent of surgery (Figure 3). The 5-year CSS rate was 80.4% in patients with more than ten nodes resected, compared with 24.5% for patients with no lymphadenectomy, for the group of patients with no omentectomy performed (P <.001). In the omentectomy group, the CSS rate was 64.4% in patients with more than ten nodes resected versus 32.3% in the no nodes resected group (P < 0.001). The 5-year CSS rate was 78.4% in patients with more than ten nodes resected compared with 30.9% in patients with no lymphadenectomy for patients with no debulking/exenteration needed, or performed (P < 0.001). In the debulking/exenteration group, the CSS was 44.6% higher in patients with more than ten nodes resected, compared with 22.5% in patients with no lymphadenectomy (P < 0.001). Patients with between one and nine nodes resected always had intermediate survival. However, the prognostic difference was less pronounced in patients that underwent a debulking or an exenteration. We analysed CSS in each FIGO stage according to histologic type and lymphadenectomy (Table 2). Results favoured lymphadenectomy in epithelial tumour whatever the stage of the disease. For clear cell and sarcoma, there was a significant ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1453
4 Rouzier et al. Figure 1. Overall and cause-specific survival according to the number of lymph nodes resected for epithelial tumours. survival benefit in patients with stage-iii and -IV disease. It fell short of reaching statistical significance in stage-ii clear cell carcinoma. Concerning sex cord stromal and germ cells tumours, no clear significant survival benefit was observed in patients who underwent lymphadenectomy. When analysed in a multivariate model, the number of lymph nodes resected was a significant prognostic factor (Table 3). An interaction term between the extent of lymphadenectomy and FIGO stage did not significantly improve the survival model (P = 0.3), suggesting that patients benefit from lymphadenectomy regardless of the stage of the disease. In contrast, the interaction between the extent of lymphadenectomy and the extent of surgery significantly improved the survival model. The extent of lymphadenectomy improved survival to a lesser degree when an extensive ovarian and peritoneal cytoreduction was performed (P < 0.001) (Figure 3; Table 3). Discussion In this study, we demonstrate that there is an association between lymphadenectomy and survival in patients with ovarian cancer, whatever the stage of the disease and the extent of surgery. This finding theoretically suggests a therapeutic effect of lymphadenectomy, but bias inherent to this retrospective methodology must be acknowledged. The therapeutic effect of lymphadenectomy is controversial for two reasons. First, patients in whom lymphadenectomy has not been performed may have been understaged. The therapeutic effect of lymphadenectomy may in fact reflect the negative impact of understaging. The pathological examination of a lymphadenectomy specimen is de facto the best evaluation of nodal status, and is more accurate than preoperative imaging or preoperative palpation. 9,10 Second, the omission of lymphadenectomy may reflect an insufficiently extensive surgery. Lymphadenectomy is thus a surrogate marker for radicality of surgery, and patients for whom lymphadenectomy has not been performed may have a poorer prognosis because of incomplete cytoreduction. Regarding understaging, it has recently been reported that the omission of lymphadenectomy in stage-i ovarian cancer may decrease survival. 7 Patients with apparent stage- I disease, but for whom lymphadenectomy has been omitted, may in fact have stage-iiic disease in the case of occult nodal metastasis. Thus, the survival difference may be explained by an underestimation of the stage of the disease. In our study, we show that the detrimental effect of understaging is logically more pronounced in patients with a higher risk of nodal metastases, namely patients with higher stage disease. Patients with apparent stage-i disease had a 10 24% risk of nodal metastasis compared with 20 30% for patients with stage-ii disease. 11 Few data are available for patients with stage-iiia B disease. Our results highlight the risks of undertreatment associated with the omission of lymphadenectomy in patients with early stage disease. Patients should be clearly informed of this risk. The deleterious effect of lymphadenectomy omission may be related to the presence of metastatic nodes. For women with stage-ii ovarian cancer, the risk of incomplete cytoreductive surgery can be estimated to be relatively low, but the incidence of lymph node involvement is around 1454 ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
5 Lymph node resection in ovarian cancer A B Figure 2. Cause-specific survival according to the number of lymph nodes resected for (A) stage-i II and (B) stage-iiib and -IIIC ovarian cancer. 20%. In this subgroup of women with a relatively low risk of intraperitoneal relapses, the impact of lymphadenectomy was particularly dramatic, underlying its specific role in survival. In patients with stage-iiic and -IV disease, the understaging effect of lymphadenectomy omission is theoretically non-existent. Even in women with advanced stages of ovarian cancer (FIGO stages III/IV), for whom the risk of incomplete cytoreductive surgery and intraperitoneal recurrence increases, our data have demonstrated the positive impact of lymphadenectomy on survival. This reinforces the concept that lymphadenectomy should be systematically recommended in women with ovarian epithelial cancer even with advanced stages of the disease if preoperative conditions of the patients remain favourable regarding blood loss and anaesthetic status. Our study confirmed the data of Chan et al. 8 that included patients from 1988 to However, our data included patients from the SEER database from 1988 to 2004, a study period where taxans were more widely used. Moreover, our study provides additional evidence of the therapeutic effect of lymphadenectomy because we evaluated and quantified the interaction between clinicopathologic characteristics and the significance of the prognostic impact of lymphadenectomy. We also report in our study the effect of lymphadenectomy in patients with non-epithelial tumours: our results suggest that lymphadenectomy ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1455
6 Rouzier et al. Figure 3. Cause-specific survival according to the number of lymph nodes resected, depending on extent of the surgery: no debulking or exenteration and debulking or exenteration. Table 2. Five-year cause-specific survival according to the histologic type, FIGO stage, and lymphadenectomy Histology FIGO stage I II III IV no lymph. Lymph. P no lymph. Lymph. P no lymph. Lymph. P no lymph. Lymph. P Epithelial* n < < < < year CSS 84% 96% 54% 81% 26% 50% 16% 33% Clear cell n < year CSS 84% 87% 57% 66% 25% 36% 13% 24% Sex cord stromal n year CSS 95% 94% 80% 82% 64% 62% 30% 57% Germ cells n year CSS 98% 99% 90% 96% 77% 89% 72% 88% Sarcoma n < year CSS 78% 80% 46% 55% 24% 39% 15% 28% *Except clear cell. Significant values are in bold. provides few or no benefits in patients with sex cord stromal and germ cell tumours. However, the relatively low number of patients (n = 2973) limits the robustness of our findings for these histologic types. Another issue is whether node sampling is as efficient as extensive lymphadenectomy for survival. In the present study, for women with early stages of ovarian cancer, we demonstrated that lymphadenectomy with more than ten 1456 ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
7 Lymph node resection in ovarian cancer Table 3. Multivatiate survival analysis HR 95% CI P Age age < 50 years 1 age > 50 years < Histology epithelial* 1 clear cell < sex cord stromal germ cell < sarcoma < Stage FIGO I 1 FIGO II < FIGO III < FIGO IV < Grade grade 1 1 grade < grade < Extent of surgery no hysterectomy 1 hysterectomy < omentectomy < debulking < Extent of lymphadenectomy >10 nodes resected nodes resected < no nodes resected < Metastatic nodes no positive nodes positive nodes < *Except clear cell. nodes removed increased the survival compared with those with less than ten nodes removed. Our results are in contrast with those of Maggioni et al., 12 who reported in a randomised trial including 268 women with FIGO stages-i/ii ovarian cancer that no difference in recurrence or death by disease was observed between women undergoing a node sampling and those who underwent a lymphadenectomy. For patients with advanced ovarian cancer, our data are in agreement with those of Beneditti Panici et al., 6 who conducted a randomised trial to compare complete lymphadenectomy with resection of bulky nodes only. They showed that the adjusted risk for the first event was significantly lower in the systematic lymphadenectomy arm than in the no-lymphadenectomy arm: the 5-year progressionfree survival rates were 31.2 and 21.6%, respectively (hazard ratio, HR = 0.75; P = 0.01). The risk of death was similar in both arms (HR = 0.97; 95% CI = ; P = 0.85). In the control group the median number of lymph nodes resected was four, and this is comparable with the group in which between one and nine nodes were resected in the current study. In the univariate analysis, we showed that there was a significant association between the extent of lymphadenectomy and survival. However, the surgical effort to resect ovarian and peritoneal disease may have biased our results. After stratification for this factor, we obtained similar results: the positive effect of lymphadenectomy was observed regardless of the extent of surgery. In the study by Beneditti Panici et al., 6 when residual disease was taken into account, the hazard ratios for occurrence of the first event and mortality from any cause were almost unchanged. In the Scotroc study including 1077 patients from the UK (n = 689) and other countries (Europe, United States, and Australia; n = 388), UK patients with no visible residual disease had a less favourable progression-free survival rate compared with patients recruited from non-uk centres who were similarly debulked (HR = 1.85; 95% CI = ; P = 0.010). 13 This observation seemed to be related to surgical practice, primarily lymphadenectomy. Combined with our results, these data suggest that lymphadenectomy may have a positive impact on prognosis, independent of cytoreduction. One should keep in mind that the majority of ovarian cancer patients died from peritoneal disease. Therefore, there is no doubt that the maximum surgical effort must be concentrated on the peritoneal cavity in order to achieve a complete debulking with no peritoneal residual tumour. There are several weaknesses in our study that must be acknowledged. First, the majority of patients did not have lymphadenectomy. When 51% of stage-i and 56% of stage- II cases had no lymph nodes removed, the distinction between understaging and detrimental therapeutic effect is challenging. It would have been interesting to determine the survival of patients with advanced stage disease based on positive nodes only. Unfortunately, this subgroup cannot be individualised from the SEER database. Second, in the absence of a detailed description of disease extent and cytoreduction, we used a surrogate marker: the surgical procedures that were performed. It can be reasonably assumed that surgical procedures were adapted to the extent of disease and surgical effort. However, they also correlate with the quality of surgery, and the omentectomy, for example, was associated with the best outcome, whereas patients who had no hysterectomy had the worse outcome (Table 2). Unfortunately, a description of carcinomatosis and surgical procedures performed to obtain complete cytoreduction are optimally reported only through relatively complex scores, as reported by Sugarbaker, Eisenkop, or Aletti ,17 Nevertheless, even with these scores, the quality of exploration (mobilisation of the liver, exploration of the omental bursa, etc.) may be associated with discrepancies between surgeons. With the surrogate marker that we used we have shown that a lack of lymphadenectomy was detrimental, independent of the surgical procedures performed. ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1457
8 Rouzier et al. Conclusion Our results suggest that no factor, apart from sex cord stromal and germ cell histology, was associated with a lack of benefit from lymphadenectomy in ovarian cancer patients. Our results contrast with findings of a randomised controlled trial. 6 Further studies are warranted to determine if our finding is related to a better staging effect, a marker of more adequate surgery effect, or a therapeutic effect of lymphadenectomy. Results of this study cannot be regarded as conclusive because of the bias inherent to the retrospective methodology, including stage migration and the possibility that the extent of lymphadenectomy is a surrogate marker for the radicality of surgery. Disclosure of interests No conflicts of interest. Contribution to authorship Study concept and design: RR, CP, and ED. Analysis and interpretation of data: RR, CB, FS, and GD. Drafting of the manuscript: RR, CB, JLB, and CP. Statistical expertise: RR. Study supervision: RR, SU, CP, and ED. Details of ethics approval This study was conducted according to the institutional and ethical rules concerning research, and was exempted from patient informed consent. Funding No funding source. j References 1 Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, CA Cancer J Clin 2004;54: Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20: Piver MS, Rose PG, Freedman MF. Change in International Federation of Gynecology and Obstetrics staging. Am J Obstet Gynecol 1988;158: Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol 1995;56: Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986;155: Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97: Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of patients. Br J Cancer 2007;96: Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007;109: Eisenkop SM, Spirtos NM. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol 2001;82: Carnino F, Fuda G, Ciccone G, Iskra L, Guercio E, Dadone D, et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol 1997;65: Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003;197: Maggioni A, Benedetti Panici P, Dell Anna T, Landoni F, Lissoni A, Pellegrino A, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006;95: Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial J Clin Oncol 2005;23: Sugarbaker PH, Jablonski K. Prognostic features of 51 colorectal and 130 appendiceal cancers with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221: Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003;90: Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol 2007;197:676.e Chéreau E, Ballester M, Selle F, Cortez A, Daraï E, Rouzier R. Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 2010;202:178.e ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer
DOI: 10.1111/j.1471-0528.2009.02214.x www.bjog.org Gynaecological oncology Pulmonary morbidity of diaphragmatic for stage III/IV ovarian cancer E Chéreau, a M Ballester, a F Selle, b A Cortez, c C Pomel,
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationLA CHIRURGIA PRIMARIA
LA CHIRURGIA PRIMARIA Manuel Maria Ianieri, MD Direttore Dipartimento: Marcello Ceccaroni, MD, PhD Dipartimento per la Tutela della Salute e della Qualità di Vita della Donna Unità Operativa di Ginecologia
More information7. Cytoreductive surgery in endometrial cancer and uterine sarcomas
Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 123-151 ISBN: 978-81-7895-484-4 Editor:
More informationTherapeutic Role of Lymph Node Resection in Endometrioid Corpus Cancer. BACKGROUND. The purpose of the current study was to determine the potential
1823 Therapeutic Role of Lymph Node Resection in Endometrioid Corpus Cancer A Study of 12,333 Patients John K. Chan, MD 1 Michael K. Cheung, BA 1 Warner K. Huh, MD 3 Kathryn Osann, PhD 4 Amreen Husain,
More informationLymphadenectomy in surgical stage I epithelial ovarian cancer
A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Lymphadenectomy in surgical stage I epithelial ovarian cancer OLIVIA SVOLGAARD 1, ØJVIND LIDEGAARD 1, MARIE LOUISE S. NIELSEN 2, LOTTE NEDERGAARD
More informationImprovements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture
Original Article J Gynecol Oncol Vol. 24, No. 4:352-358 pissn 2005-0380 eissn 2005-0399 Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor
More informationThe role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
Radiology and Oncology Ljubljana Slovenia www.radioloncol.com research article 341 The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Erik Škof 1, Sebastjan
More informationResidual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany
Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences
More informationLaparoscopic Management of Early Stage Endometrial Cancer. B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G.
Laparoscopic Management of Early Stage Endometrial Cancer B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G. Mage Early Stage of Endometrial Cancer most of cases diagnosed (clinical
More informationNormal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases A Case Report and Literature Review
doi:10.21873/invivo.11250 Normal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases A Case Report and Literature Review NICOLAE BACALBASA 1, IRINA BALESCU 2, CRISTIAN BALALAU
More informationLAPAROSCOPY and OVARIAN CANCER
LAPAROSCOPY and OVARIAN CANCER J. DAUPLAT Clermont-Ferrand France UNIVERSITÉ D'AUVERGNE CLERMONT 1 1 - PROPHYLACTIC OOPHORECTOMY 2 - DIAGNOSIS 3 - EARLY STAGES : STAGING 4 - ADVANCED STAGES - ASSESSMENT
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationRESEARCH ARTICLE. Usanee Chatchotikawong 1, Irene Ruengkhachorn 1 *, Chairat Leelaphatanadit 1, Nisarat Phithakwatchara 2. Abstract.
RESEARCH ARTICLE 8-year Analysis of the Prevalence of Lymph Nodes Metastasis, Oncologic and Pregnancy Outcomes in Apparent Early-Stage Malignant Ovarian Germ Cell Tumors Usanee Chatchotikawong 1, Irene
More informationIn the United States, ovarian cancer is the leading
Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer Giovanni D. Aletti, MD, Sean C. Dowdy, MD, Bobbie S. Gostout, MD, Monica B. Jones, MD, C. Robert Stanhope, MD, Timothy
More informationBACKGROUND. The objective of this study was to determine the impact of malignant
1397 The Clinical Significance of Malignant Pleural Effusions in Patients with Optimally Debulked Ovarian Carcinoma Ram Eitan, M.D. Douglas A. Levine, M.D. Nadeem Abu-Rustum, M.D. Yukio Sonoda, M.D. Jae
More informationOvarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?
Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial
More informationPrognostic Significance of Systematic Lymphadenectomy as Part of Primary Debulking Surgery in Patients with Ovarian Cancer
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (5), Page 1008-1015 Prognostic Significance of Systematic Lymphadenectomy as Part of Primary Debulking Surgery in Patients with Ovarian
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationAbstract. Int J Gynecol Cancer 2007
Int J Gynecol Cancer 2007 Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis D.C. SMITH*, O.K. MACDONALD*, C.M. LEEy & D.K. GAFFNEY*
More informationIntroduction. Abstract
Gynecologic Oncology 103 (2006) 1083 1090 www.elsevier.com/locate/ygyno The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC
More informationENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media
For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096
More informationRole of Pelvic and Para-aortic Lymph Node Metastases in Optimally Cytoreduced Advanced Ovarian Cancer
Role of Pelvic and Para-aortic Lymph Node Metastases in Optimally Cytoreduced Advanced Ovarian Cancer CORNELIA BACHMANN 1, ROBERT BACHMANN 3, SARA Y. BRUCKER 1, ANETTE STAEBLER 2, FALKO FEND 2, EVA-MARIA
More informationStage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy
Original Investigation 33 Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy Gökhan Boyraz, Derman Başaran, Mehmet
More informationSpecialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients
British Journal of Obstetrics and Gynaecology November 1999, Vol106, pp. 1130-1136 Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients *E. J. Junor
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationComparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
J Gynecol Oncol. 2016 Sep;27(5):e46 pissn 2005-0380 eissn 2005-0399 Original Article Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial
More informationPrognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis
NJOG 2009 June-July; 4 (1): 19-24 Prognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis Eliza Shrestha 1, Xiong Ying 1,2, Liang Li-Zhi 1,2, Zheng Min 1,2,
More informationSurgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
More informationBACKGROUND: STUDY DESIGN: RESULTS: CONCLUSIONS: Disclosure Information: Nothing to disclose.
Surgical Procedures and Morbidities of Diaphragmatic Surgery in Patients Undergoing Initial or Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Sebastien Gouy, MD, Elisabeth Chereau, MD, Ana
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationMarcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationRelapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationWomen s Imaging Original Research
Women s Imaging Original Research Lakhman et al. Postoperative CT as Prognostic Biomarker in Gynecologic Cancer Women s Imaging Original Research Yulia Lakhman 1 Oguz Akin 1 Michael J. Sohn 1 Junting Zheng
More informationTHE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER
THE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER Casey A. Boyd, Jaime Benarroch, Kristin M. Sheffield, Yimei Han, Catherine D. Cooksley, Taylor S. Riall Department of Surgery The University of Texas Medical
More informationHysterectomy-Corrected Rates of Endometrial Cancer among Women of Reproductive Age
Hysterectomy-Corrected Rates of Endometrial Cancer among Women of Reproductive Age Annie Noone noonea@mail.nih.gov NAACCR 2017 Albuquerque, NM Motivation Cancer incidence rates are typically calculated
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationImpact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study
J Gynecol Oncol. 2018 Jan;29(1):e12 pissn 2005-0380 eissn 2005-0399 Original Article Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology
More informationThe Effect of Changing Hysterectomy Prevalence on Trends in Endometrial Cancer, SEER
The Effect of Changing Hysterectomy Prevalence on Trends in Endometrial Cancer, SEER 1992-2008 Annie Noone noonea@mail.nih.gov Missy Jamison, Lynn Ries, Brenda Edwards NAACCR 2012 Portland, OR Outline
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationAbstract. Materials and methods
Int J Gynecol Cancer 2006, 16, 490 495 Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures A.-A.K. TENTES, C.G. MIRELIS, S.K. MARKAKIDIS,
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationIndex. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationPrognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
J Gynecol Oncol Vol. 20, No. 3:158-163, September 2009 DOI:10.3802/jgo.2009.20.3.158 Original Article Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationOvarian cancer: clinical practice the Arabic perspective
Lead Group Log Ovarian cancer: clinical practice the Arabic perspective Experience of Hôtel-Dieu de France University Hospital (Beirut, LEBANON) in supraradical surgery for ovarian cancer David ATALLAH
More informationOvarian cancer: patterns of care in Victoria during
RESEARCH Ovarian cancer: patterns of care in Victoria during 1993 1995 Marisa Grossi, Michael A Quinn, Vicky J Thursfield, Prudence A Francis, Robert M Rome, Robert S Planner and Graham G Giles IN VICTORIA,
More informationViews and counter views The role of pelvic and para-aortic lymph node dissection in the surgical treatment of endometrial cancer: a view from the USA
The Obstetrician & Gynaecologist 10.1576/toag.11.3.199.27505 http://onlinetog.org 2009;11:199 204 Views and counter views Views and counter views The role of pelvic and para-aortic lymph node dissection
More informationSurgery in Recurrent Ovarian Cancer - an emerging area of evidence -
Surgery in Recurrent Ovarian Cancer - an emerging area of evidence - Andreas du Bois Kliniken Essen Mitte (KEM), Germany AdB 2018 A long and winding road to define the role of surgery in relapsed OC called
More informationSURGERY OF RECURRENCIES
La chirurgia Bergamo, delle 6 th May recidive 2011 SURGERY OF RECURRENCIES Pierluigi Benedetti Panici Calcagno Marco, Gasparri Maria Luisa, Domenici Lavinia, Bellati Filippo CANCRO EPITELIALE DELL OVAIO:
More informationPrognostic factors in sex cord stromal tumors of the ovary
Research article Prognostic factors in sex cord stromal tumors of the ovary Achraf HADIJI 1, Tarak DAMAK 1, Lamia CHARFI 2, Jamel BEN HASSOUNA 1, Imen OUESLETI 1, Riadh CHARGUI 1, Khaled RAHAL 1. 1 Service
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationSurgical Complexity Impact on Survival After Complete Cytoreductive Surgery for Advanced Ovarian Cancer
Ann Surg Oncol DOI 10.1245/s10434-015-5069-z ORIGINAL ARTICLE GYNECOLOGIC ONCOLOGY Surgical Complexity Impact on Survival After Complete Cytoreductive Surgery for Advanced Ovarian Cancer A. Martinez, MD,
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationSignificance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma
ORIGINAL STUDY Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma Jeong-Yeol Park, MD, PhD, Dae-Yeon Kim, MD, PhD, Dae-Shik Suh, MD, PhD, Jong-Hyeok Kim, MD, PhD, Yong-Man
More informationPrediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer
Original Article J Gynecol Oncol Vol. 22, No. 4:269-274 pissn 2005-0380 eissn 2005-0399 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationIs Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?
e-issn 1643-3750 DOI: 10.12659/MSM.897291 Received: 2015.12.27 Accepted: 2016.01.13 Published: 2016.02.08 Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Authors Contribution:
More informationPrognostic significance of positive lymph node number in early cervical cancer
1052 Prognostic significance of positive lymph node number in early cervical cancer JUNG WOO PARK and JONG WOON BAE Department of Obstetrics and Gynecology, Dong A University Hospital, Dong A University
More informationThe impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients ( 40 years old) with borderline ovarian tumors
Fang et al. BMC Cancer (2018) 18:1147 https://doi.org/10.1186/s12885-018-4932-2 RESEARCH ARTICLE Open Access The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationThe clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population
Zhang et al. BMC Cancer (2019) 19:22 https://doi.org/10.1186/s12885-018-5147-2 RESEARCH ARTICLE Open Access The clinicopathological features and treatment modalities associated with survival of neuroendocrine
More informationSurvival impact of cytoreductive surgery ın advanced stage EOC
Survival impact of cytoreductive surgery ın advanced stage EOC Ayhan Ali, MD Baskent University School of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 1 OVARIAN CANCER
More informationComparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer
DOI 10.1007/s13224-013-0425-z ORIGINAL ARTICLE Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer Sayyah-Melli Manizheh Zonoozi
More informationUTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS
Review Journal of Translational Medicine and Research, volume 19, no. 1-2, 2014 UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS N. Bacalbaæa 1, A. Traistaru 2, I. Bãlescu 3 1 Carol Davila University of Medicine
More informationPrognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study
/, Vol. 7, No. 7 Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study Juan Zhou 1,*, Zhen-Yu He 2,*, Feng-Yan Li 2,* Jia-Yuan
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationFactors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage
Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Jessica Johns, MD Jeffrey Killeen, MD Robert Kim, MD Hyeong Jun Ahn, PhD None Disclosures
More informationRandomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis
British Journal of Cancer (2006) 95, 699 704 All rights reserved 0007 0920/06 $30.00 www.bjcancer.com Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationOutcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single
More informationSurveillance report Published: 17 March 2016 nice.org.uk
Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationThe role of surgical resection in the management of malignant
ORIGINAL ARTICLE Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER])
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationResearch Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy
International Surgical Oncology Volume 2012, Article ID 307670, 7 pages doi:10.1155/2012/307670 Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationIncidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience
RESEARCH ARTICLE Incidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience Atthapon Jaishuen 1, Kate Kunakornporamat 1, Boonlert Viriyapak 1, Mongkol Benjapibal
More informationThe Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer
doi:10.21873/anticanres.11111 The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer MIKKEL ROSENDAHL, BERIT JUL MOSGAARD and CLAUS
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons
A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationStage 3 ovarian cancer survival rate
Search Stage 3 ovarian cancer survival rate 19-5-2017 If you've been diagnosed with ovarian cancer, it's natural to wonder about your prognosis. Learn about survival rates, outlook, and more. Take the
More informationConventional Gastrectomy for Gastric Cancer. Franklin Wright UCHSC Department of Surgery Grand Rounds January 14, 2008
Conventional Gastrectomy for Gastric Cancer Franklin Wright UCHSC Department of Surgery Grand Rounds January 14, 2008 Overview Gastric Adenocarcinoma Conventional vs Radical Lymphadenectomy Non-randomized
More informationStage 3 ovarian cancer survival rate
Stage 3 ovarian cancer survival rate Gogamz Menu The latest ovarian cancer survival statistics for the UK for Health Professionals. See data for age, trends over time, stage at diagnosis and more. 5-8-2014
More informationsurgical staging g in early endometrial cancer
Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More information